as 01-17-2025 4:00pm EST
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Founded: | 2007 | Country: | United States |
Employees: | N/A | City: | CRANFORD |
Market Cap: | 28.4M | IPO Year: | N/A |
Target Price: | $54.50 | AVG Volume (30 days): | 185.5K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -5.97 | EPS Growth: | N/A |
52 Week Low/High: | $2.44 - $26.75 | Next Earning Date: | 02-12-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 216.25% |
CTXR Breaking Stock News: Dive into CTXR Ticker-Specific Updates for Smart Investing
PR Newswire
11 days ago
MT Newswires
11 days ago
MT Newswires
11 days ago
MT Newswires
11 days ago
PR Newswire
12 days ago
TipRanks
12 days ago
MT Newswires
12 days ago
MT Newswires
13 days ago
The information presented on this page, "CTXR Citius Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.